BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.63
-0.02 (-0.26%)
At close: Sep 26, 2025, 4:00 PM EDT
7.65
+0.02 (0.26%)
After-hours: Sep 26, 2025, 5:53 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for BioCryst Pharmaceuticals stock ranges from a low of $11 to a high of $30. The average analyst price target of $16.7 forecasts a 118.87% increase in the stock price over the next year.
Price Target: $16.70 (+118.87%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 4, 2025.
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +122.80% | Aug 4, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $13 → $15 | Strong Buy | Maintains | $13 → $15 | +96.59% | Jul 1, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $13 | Buy | Reiterates | $13 | +70.38% | Jun 30, 2025 |
| Wedbush | Wedbush | Buy Maintains $16 → $18 | Buy | Maintains | $16 → $18 | +135.91% | Jun 30, 2025 |
| Needham | Needham | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +122.80% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
637.02M
from 450.71M
Increased by 41.34%
Revenue Next Year
675.96M
from 637.02M
Increased by 6.11%
EPS This Year
0.09
from -0.43
EPS Next Year
0.56
from 0.09
Increased by 538.48%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 662.7M | 737.1M | |||
| Avg | 637.0M | 676.0M | |||
| Low | 597.8M | 603.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.0% | 15.7% | |||
| Avg | 41.3% | 6.1% | |||
| Low | 32.6% | -5.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.20 | 0.96 | |||
| Avg | 0.09 | 0.56 | |||
| Low | 0.04 | 0.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 991.0% | |||
| Avg | - | 538.5% | |||
| Low | - | 246.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.